Study Purpose:
Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation.The major goal of the project is to develop human iPS cells from various types of cell cultures or lines from existing collections. The IPS cells will be developed for modeling diseases, for developing the technology that may eventually allow the use of IPS cells for transplantation therapy, and for basic research.
Study Status:
Recruiting
Disease:
Amyotrophic Lateral Sclerosis
Study Type:
Observational
Type of Intervention:
N/A
Intervention Name:
N/A
Placebo:
N/A
Phase:
N/A
Study Chair(s)/Principal Investigator(s):
Benjamin E Reubinoff, MD PhD, Chairman of Department of Obstetrics & Gynecology/IVF, Hadassah Ein Kerem
Clinicaltrials.gov ID:
Neals Affiliated?
No
Coordinating Center Contact Information
Benjamin E. Reubinoff, M.D. PhD. / email hidden; JavaScript is required / 011-972-2-677-4569
Full Study Summary:
The potential to reprogram somatic cells into an embryonic state raises multiple basic research questions related both to the process of reprogramming and the properties of iPS cells. We will use various approaches to study the molecular mechanisms and processes that occur during reprogramming. We will use various experimental systems to characterize and study the properties of the iPS cells, their biology, developmental potential, capability to give rise to functional differentiated progeny etc.
We will induce the differentiation of the iPS cells towards specific cell lineages and the progeny can be used to study the pathogenesis of diseases. They will be used for developing new therapeutic approaches and for high throughput screening of factors for potential toxic or therapeutic effects.
All samples will be non-identified.
We will induce the differentiation of the iPS cells towards specific cell lineages and the progeny can be used to study the pathogenesis of diseases. They will be used for developing new therapeutic approaches and for high throughput screening of factors for potential toxic or therapeutic effects.
All samples will be non-identified.
Study Sponsor:
Hadassah Medical Organization
Estimated Enrollment:
25
Estimated Study Start Date:
11 / 01 / 2008
Estimated Study Completion Date:
12 / 01 / 2025
Posting Last Modified Date:
02 / 16 / 2023
Date Study Added to neals.org:
12 / 03 / 2008
Minimum Age:
18 Years
Maximum Age:
N/A
Inclusion Criteria:- Volunteers
- Male and Female
Exclusion Criteria:
- Below the official age of consent
Hadassah Medical Organization - Ein Kerem Campus | Recruiting
Hadas Lemberg, PhD / 011-972-2-677-6095 / email hidden; JavaScript is required
Jerusalem 91120
Israel
Hadassah Ein Kerem | Recruiting
Benjamin E Reubinoff, Professor / 972-2-6776424/5 / email hidden; JavaScript is required
Shelly E Tannenbaum, MSQA / 972-2-6777945 / email hidden; JavaScript is required
Jerusalem 9112100
Israel